GlassScriptPhysician profile
William S Loui
NPI 1346217718
$11,719.64
in general payments reported to CMS, 2019-2025
59 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $815 · 2021: $2,174 · 2022: $1,246 · 2023: $1,214 · 2024: $1,639 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,969 · Education: $647 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.88 |
| Education | $646.69 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,508.13 | 2019-2025 | |
| Astellas Pharma US INC | $1,404.68 | 2019-2025 | Xtandi, Xospata, Padcev |
| Pfizer INC. | $1,027.58 | 2019-2025 | |
| Janssen Biotech, INC. | $691.91 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $662.59 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $653.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $578.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $545.74 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $535.08 | 2019-2025 | Tecentriq, Gavreto, Alecensa |
| Alexion Pharmaceuticals, INC. | $453.63 | 2022-2025 | Ultomiris, Soliris, Strensiq |
| Amgen INC. | $270.21 | 2021-2025 | Uplizna, Krystexxa |
| Pharmacyclics LLC, An Abbvie Company | $210.99 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $203.34 | 2019-2025 | |
| Exelixis INC. | $169.28 | 2019-2025 | Cabometyx |
| Eisai INC. | $168.23 | 2020-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $164.83 | 2019-2025 | |
| Abbvie INC. | $156.04 | 2024-2025 | |
| Aadi Bioscience, INC. | $150.00 | 2023 | Fyarro |
| Beone Medicines USA, INC. | $148.90 | 2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $109.81 | 2021-2023 | Beleodaq |
| Seagen INC. | $108.50 | 2019-2023 | Padcev |
| Blueprint Medicines Corporation | $97.52 | 2020-2025 | Ayvakit |
| Foundation Medicine, INC. | $90.17 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $86.46 | 2025 | Monoferric |
| Sobi, INC | $86.37 | 2022-2024 | |
| Glaxosmithkline, LLC. | $82.15 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Sumitomo Pharma America, INC. | $80.03 | 2025 | Orgovyx |
| Array Biopharma INC | $79.87 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $76.81 | 2022-2024 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $72.59 | 2023-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $66.35 | 2023-2025 | Xpovio |
| Pharmaessentia USA Corporation | $64.40 | 2023-2024 | Besremi |
| Caris Mpi, INC. | $64.10 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $63.90 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $58.68 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Eusa Pharma (US) LLC | $58.17 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $51.54 | 2023-2025 | Enjaymo, Sylvant |
| Dova Pharmaceuticals | $51.42 | 2019-2020 | |
| Springworks Therapeutics, INC. | $48.42 | 2025 | Ogsiveo |
| Kyowa Kirin, INC. | $44.90 | 2022-2024 | Poteligeo |
| Lilly USA, LLC | $44.58 | 2021-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $36.76 | 2019-2025 | |
| Gilead Sciences, INC. | $36.57 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $35.62 | 2025 | |
| Syndax Pharmaceuticals, INC. | $31.98 | 2025 | |
| Coherus Oncology, INC. | $30.48 | 2025 | Loqtorzi |
| Aveo Pharmaceuticals, INC. | $30.12 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $27.93 | 2023-2025 | Libtayo |
| Servier Pharmaceuticals LLC | $25.87 | 2025 | |
| Sun Pharmaceutical Industries INC. | $24.41 | 2023 | Odomzo, Yonsa |
| Novo Nordisk INC | $23.69 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.48 | 2019 | |
| Celgene Corporation | $21.94 | 2019 | |
| Genentech, INC. | $20.42 | 2025 | Columvi |
| Apellis Pharmaceuticals, INC. | $19.41 | 2024 | Empaveli |
| Allergan, INC. | $14.90 | 2019 | |
| Verastem, INC. | $14.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 | |
| Beigene USA, INC. | $4.02 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Loui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.